3-M syndrome associated with growth hormone deficiency: 18 year follow-up of a patient.

Détails

Ressource 1Télécharger: BIB_3576B4FB1CE9.P001.pdf (2839.69 [Ko])
Etat: Public
Version: de l'auteur
ID Serval
serval:BIB_3576B4FB1CE9
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Etude de cas (case report): rapporte une observation et la commente brièvement.
Collection
Publications
Institution
Titre
3-M syndrome associated with growth hormone deficiency: 18 year follow-up of a patient.
Périodique
Italian Journal of Pediatrics
Auteur(s)
Meazza C., Lausch E., Pagani S., Bozzola E., Calcaterra V., Superti-Furga A., Silengo M., Bozzola M.
ISSN
1824-7288 (Electronic)
ISSN-L
1720-8424
Statut éditorial
Publié
Date de publication
2013
Volume
39
Numéro
21
Pages
1-6
Langue
anglais
Notes
Publication types: Journal Article Publication Status: epublish. PDF type: case report
Résumé
3-M syndrome is a rare autosomal recessive disorder that causes short stature, unusual facial features and skeletal abnormalities. Mutations in the CUL7, OBSL1 and CCDC8 genes could be responsible for 3-M syndrome.Here we describe the growth and evolution of dismorphic features of an Italian boy with 3-M syndrome and growth hormone deficiency (GHD) from birth until adulthood. He was born full term with a very low birth weight (2400 g=-3.36 standard deviation score, SDS) and length (40.0 cm =-6.53 SDS). At birth he presented with a broad, fleshy nose with anteverted nostrils, thick and patulous lips, a square chin, curvilinear shaped eyebrows without synophrys, short thorax and long slender bones. Then, during childhood tall vertebral bodies, hip dislocation, transverse chest groove, winged scapulae and hyperextensible joints became more evident and the diagnosis of 3-M syndrome was made; this was also confirmed by the finding of a homozygous deletion in exon 18 of the CUL7 gene, which has not been previously described.The patient also exhibited severe GHD (GH <5 ng/ml) and from the age of 18 months was treated with rhGH. Notwithstanding the early start of therapy and good compliance, his growth rate was always very low, except for the first two years of treatment and he achieved a final height of 132 cm (-6.42 SDS).
Pubmed
Web of science
Open Access
Oui
Création de la notice
03/05/2013 20:44
Dernière modification de la notice
20/08/2019 14:22
Données d'usage